Biomarkers World Europe - list of speakers 

Khusru Asadullah is Vice President and Head of Global Biomarker at Bayer HealthCare Pharmaceuticals. Before this he headed Target Discovery and Inflammation and Immunology research at Bayer Schering Pharma. He is a Professor of Medicine at the University Hospital Berlin. He graduated from the Medical School Charité, Berlin and the Harvard Business ...

Jiri Aubrecht is a Senior Director and Group Lead of Safety Biomarker Laboratories at Pfizer Worldwide Research and Development in Groton, CT. His research interests are the application of systems biology-based approaches for investigating toxic mechanisms and biomarker development with emphasis on qualification of novel biomarkers for risk...

Joined TSB in Oct 2010 as the lead specialist in the Stratified Medicine Innovation Platform. Has over 20 years experience working in SME in UK, in drug development, business and corporate development roles. BSc in medical microbiology and PhD in Immunology from Edinburgh University

Dr. Richard Buller is the Vice President of Translational Oncology in the Pfizer Oncology Business Unit. His group is responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates. Recent success is reflected by the approval of critoztinib for the treatment of ...

John Burkhardt is Global Head of Preclinical Safety at Abbott Laboratories, where he is responsible for all aspects of Toxicology, Pathology, Comparative Medicine, and related fields. John joined Abbott in 2008, following a nearly 15 year career at Pfizer. John holds DVM and PhD degrees from Purdue University, along with board certifications by...

Nigel Dallow is a Director of Clinical Statistics at GlaxoSmithKline supporting the respiratory area. Nigel has vast experience in working in drug development especially in the early phase area having worked at GSK for 17 years. Though his experiences, Nigel has a strong ethos in re-engineering phase II and is dedicated to exploring alternative...

Aiden Flynn has worked for more than 18 years in the development and application statistics and modelling to drug discovery and development. After seven years as a Lecturer at University College London, he spent ten years at GlaxoSmithKline as Director of statistical support for biomarker studies across research and development. Currently, he is ...

Dr Elizabeth Foot is Chief Executive Officer for London Genetics International, a specialist company created to facilitate partnerships between industry and academic centres of excellence in genetics and the field of stratified medicine. She has extensive experience of medical research and clinical drug development gained within academia, UK...

Mark Graham is Senior Principal Scientist and Global Discipline Leader for Discovery Safety. He has published more than 30 peer reviewed papers and many presentations and lectures at scientific conferences. Currently a member of the ‘Committee on Toxicity (COT)’ which provides independent, expert advice on all aspects of chemical toxicity to...

Carolina Haefliger, born and educated in Argentina, graduated with Honors as M.D. in the Universidad del Salvador, Buenos Aires. She is Specialist in Medical Genetics and worked in the field of Experimental Genetics, at the National Center of Medical Genetics, Argentina. She then moved to Berlin, Germany, where she worked for almost 5 years at...

Abdel Halim is an internationally recognized biomarker and clinical laboratory professional with more than 25 years of experience in all aspects of biomarker discovery, development, validation, and applications in patient management and pharmaceutical development. He is an expert in all biomarker techniques and platforms from safety lab...

Dr Hernandez-Fuentes completed an MD in Universidad Complutense and her PhD in Immunology in Universidad de Alcalá, both in Madrid, Spain. In 1998 she came to the UK to do her first post-doc with Professor Robert Lechler, then at Imperial College, Hammersmith Hospital. In 2005 the research group moved to King´s College London and from November...

Research on Alzheimer's disease and therapy at Harvard, Pharmacia, Pfizer, and Abbott. Drug discovery experience from target discovery to preclinical pharmacology, translational research, and clinical biomarker studies. Co-discovered Alzheimer's gene Presenilin 2 (PS2) and gamma-secretase gene PEN2.

Robert Miller is the Chief Consultancy Officer and product development consultant for Aptiv Solutions. Dr Miller provides medical input into the strategy and design of development programmes in multiple indications (including those in inflammation, ischaemia-reperfusion, cardiovascular, respiratory, and oncological indications). Dr Miller...

Dr. Yoshiya Oda received his BS degree in Pharmaceutical Science from Kyoto University (Japan), and he earned his PhD from Kyoto University. He is working in Eisai (Japanese pharmaceutical company) for 23 years. At the same time, Dr. Oda also served as an associate professor at Medical Institute of Bioregulation in Kyushu University and Graduate...

Dr. Paweletz has been involved in basic and clinical research over his entire career, and has extensive experience at NIH and in industry. He has special expertise in cancer, proteomics, and systems biology. His most recent experience has been at Merck and Company as Research Fellow in the Molecular Biomarkers Department. He joined Merck in...

James is the Director of Stratified Medicine at Cancer Research UK, the UK charity spending £300m on cancer research. He leads the Stratified Medicine Programme, a £5.5m national partnership to improve NHS molecular pathology and research in cancer. It is co-funded by AstraZeneca and Pfizer, and coordinated with the Technology Strategy Board’s...

Studied medicine at the University of the Witwatersrand, Johannesburg, [BSc Hons in Physiology and Medical Biochemistry (1988) and MBBCh (1990)]. Received specialist training in psychiatry at the University of Cape Town from 1993-1997 (FCPsych SA, 1996). Trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London...

Chris Roberts, Ph.D., is Director of the Research Solutions Bioinformatics Team in the Informatics and Analysis Department at Merck Research Laboratories and is based at Merck's Boston MA research facility. He leads at team of bioinformaticists that are localized at Merck's research facilities in Boston, New Jersey, and Pennsylvania. The...

Jochen Theis is the founder and principle consultant of InHeCon, an integrated healthcare consultancy serving clients in the pharma/biotech, diagnostics, and venture capital industries. InHeCon focuses on modern, rational, and decision focussed research, development, and commercialisation of medicines and diagnostics through integration of...

Marie-Anne Valentin received a PhD in Pharmacology from the University of Nancy (France) in 2001 and used a broad technology portfolio to study protein function during subsequent postdoctoral fellowship at the University College of London (UK). In 2004, Dr Valentin joined Sanofi-Aventis. Her work concerned the identification and validation of new...

Dr. Villacian, currently Chief Medical Officer at Janssen Diagnostics, a division of Janssen Pharmaceutica, holds an MD Degree (Mexico) and trained in the US. He is certified by the American Board of Internal Medicine as an Internist and Infectious Diseases specialist. He has extensive work experience in the public health, academic and hospital...

Roche Genentech R&D is driven by two autonomous R&D centers gRED, Genentech & pRED, Roche Pharma Research & Exploratory Development. Andreas Wallnoefer is the Global Head of pRED Development and is a member of the pRED Leadership Team. He is also a core member of both the Exploratory (ESPC) and the Late stage (LSPC) Strategic Portfolio...

Richard leads a lab focused on the application of mass-spectrometry to achieve high confidence read outs of biomarkers across the R&D organization at Actelion. The work covers both protein and metabolite measurements. The Lab is embedded in the translational-science group, which aims to bring new biomarkers into the early clinical phases. Richard...